Prior work has shown that T2DM is associated with reduced CBF (Bangen et al., 2018) and also modifies the relationship between AD risk factors (e.g., apolipoprotein E [APOE] ɛ4 allele, subtle cognitive decline, tau), and future functional decline (Thomas, et al., 2020a, b). This evidence concerns the gene MAPT and Alzheimer disease.